For hospitals considering enrollment in the Federal 340B Drug Pricing Program, the Health Resources and Services Administration's recent Omnibus Guidance could have significant impact on plans and operations.
Feb. 4, 2016
/PRNewswire/ -- For hospitals considering enrollment in the Federal 340B Drug Pricing Program, or those already participating in the program, the Health Resources and Services Administration's (HRSA) recent Omnibus Guidance, often referred to as the 'Mega-Guidance,' could have significant impact on plans and operations, once the final guidance is published in
In a new blog post on the Cardinal Health thought leadership site, Essential Insights, Daniel Neal, director of 340B Product and Service Marketing, summarizes the Mega-Guidance's key proposed changes, including a new requirement that has patients meet six conditions — an increase from the current three – for eligibility to receive medication purchased at 340B prices, as well as a revised criteria for qualifying sites of care.
As a result of the Mega-Guidance, Neal discusses four ways hospitals can prepare for the potential impact of the proposed ruling, including:
"As with any worthwhile initiative — especially in today's evolving healthcare landscape – creating a strong 340B program for your hospital is best viewed not as a destination, but as a journey," says Neal. "When managed correctly, including appropriate oversight, planning and preparation, this program can continue to be a cornerstone of an eligible hospital's ability to improve access to care and sustain their community mission."
To learn more about the Mega-Guidance changes and Neal's insight, read his full blog post on Cardinal Health's Essential Insights.